Evaluating the true cost of CJC-1295 DAC for laboratory research requires analyzing sequence purity, lot-specific analytical documentation, and structural stability. This technical guide outlines the procurement economics, biochemical characteristics, and verification protocols for high-purity CJC-1295 DAC in preclinical settings.
Evaluating the true cost of CJC-1295 DAC for laboratory research requires analyzing sequence purity, lot-specific analytical documentation, and structural stability. This technical guide outlines the procurement economics, biochemical characteristics, and verification protocols for high-purity CJC-1295 DAC in preclinical settings.
The true CJC-1295 DAC cost in laboratory environments is determined by verified purity, sequence integrity, and bio-availability rather than simple milligram pricing. High-grade research CJC-1295 DAC requires rigorous RP-HPLC and mass spectrometry validation to confirm that the Drug Affinity Complex modification remains intact. Purchasing unverified peptides introduces experimental variance, risking project delays and compromised data.
When evaluating market pricing for CJC-1295 DAC, principal investigators must look beyond base price per vial. Essential cost factors include whether the supplier provides lot-specific third-party certificates of analysis (COAs), performs quantitative endotoxin screening, and manufactures in US-based GMP-compliant facilities. Skimping on analytical transparency often leads to higher downstream costs due to degraded samples, incomplete bioconjugation, or bio-incompatible contaminants.
CJC-1295 with DAC is a synthetic 30-amino-acid analog of human growth hormone-releasing hormone (GHRH). The base peptide sequence represents a modified version of native GHRH(1-29), optimized with specific amino acid substitutions—specifically D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27—to enhance resistance to cleavage by dipeptidyl peptidase-IV (DPP-IV).
The defining modification of this compound is the addition of the Drug Affinity Complex (DAC) reactive group attached to a lysine residue at the C-terminus via a linker. The DAC group consists of a maleimidopropionic acid (MPA) moiety. In biochemical assays and animal models, this MPA linker selectively forms a covalent bond with the free thiol group of Cys34 on circulating serum albumin. This irreversible bioconjugation protects the peptide from renal clearance and enzymatic degradation, dramatically extending its half-life in target research models.
In preclinical literature, CJC-1295 DAC is studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research. Unlike unmodified GHRH or short-acting analogs that elicit brief, episodic GH spikes, CJC-1295 DAC provides a prolonged, continuous stimulation of the pituitary GHRH receptors.
Preclinical studies suggest that this continuous activation leads to elevated baseline growth hormone concentrations and sustained synthesis of insulin-like growth factor 1 (IGF-1) in hepatic tissues. Researchers utilize this compound to investigate long-term cellular proliferation, extracellular matrix remodeling, muscle protein turnover, and metabolic signaling pathways without requiring multiple daily dosing administration in rodent or culture models. For comprehensive data on secretagogue profiles, consult our growth hormone research library.
The synthesis of CJC-1295 DAC is technically more demanding than that of standard linear peptides. Solid-phase peptide synthesis (SPPS) must carefully integrate the hydrophobic MPA linker without inducing premature side reactions or aggregation. Subsequent purification using reversed-phase high-performance liquid chromatography (RP-HPLC) requires multi-stage gradient elution to separate the fully conjugated CJC-1295 DAC from truncated or non-functionalized sequence fragments.
Because of these additional step yields and specialized chemical inputs, high-purity CJC-1295 DAC carries higher manufacturing overhead than unmodified peptides. Low-cost market alternatives frequently bypass secondary purification stages or forego rigorous mass spec verification, resulting in products contaminated with free MPA, incomplete peptides, or residual trifluoroacetic acid (TFA) salts that can alter cell culture viability.
To ensure reproducible experimental outcomes, institutional research facilities require full analytical transparency. Every batch of CJC-1295 DAC distributed by PX1 Research undergoes independent verification by an accredited ISO 17025 laboratory. This testing protocol evaluates both purity percentage and precise molecular weight.
RP-HPLC chromatograms confirm a single main peak with a baseline purity exceeding 98%. Simultaneously, Electrospray Ionization Mass Spectrometry (ESI-MS) confirms the target molecular weight of 3647.28 Da, proving that the MPA linker is fully conjugated to the C-terminal lysine. Researchers can view and download lot-specific COAs directly from PX1 Research to verify sequence purity before beginning reconstitution.
Bacterial endotoxins (lipopolysaccharides) represent a significant confounding variable in biomedical research. In cell culture models, endotoxins can trigger unintended inflammatory cascades through Toll-like receptor 4 (TLR4) pathways, skewing gene expression data and cell survival assays. In animal studies, elevated endotoxin levels can induce systemic immune responses unrelated to the peptide's mechanism.
PX1 Research subjects every lot of CJC-1295 DAC to quantitative Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain strictly below <0.5 EU/mg. Enforcing rigorous endotoxin testing safeguards research integrity and validates that observed biological effects stem exclusively from GHRH receptor stimulation.
When designing preclinical protocols, researchers frequently compare long-acting CJC-1295 DAC against non-conjugated GHRH analogs and complementary growth hormone secretagogues. Selecting the appropriate compound depends on whether the protocol requires continuous receptor activation or pulsatile GH release.
For instance, CJC-1295 No DAC (also known as Modified GRF 1-29) lacks the maleimide linker, yielding a rapid elimination half-life suited for simulating natural episodic GH pulses. Similarly, Sermorelin represents the truncated 29-amino-acid native sequence with a brief duration of action. When researchers aim to evaluate synergistic GH secretion, they often pair GHRH analogs with ghrelin receptor agonists such as Ipamorelin. The table below highlights key functional differences across these research compounds:
Proper reconstitution technique is critical to preserving the molecular stability of CJC-1295 DAC and preventing premature hydrolysis of the reactive maleimide group. Lyophilized peptide vials should be allowed to equilibrate to room temperature before reconstitution to minimize condensation inside the container.
Reconstitution should be performed using sterile bacteriostatic water containing 0.9% benzyl alcohol or lab-grade reconstitution buffers, depending on downstream assay requirements. Reagents should be introduced along the glass wall of the vial, followed by gentle swirling. Severe agitation or vortexing must be avoided to prevent mechanical shearing of the peptide chain. For step-by-step laboratory guidelines, review our detailed peptide reconstitution guide.
In lyophilized powder form, CJC-1295 DAC remains stable at -20°C for extended periods, provided it is stored away from moisture and direct light. Long-term storage for baseline laboratory inventory is optimal at -80°C.
Once reconstituted into solution, the peptide should be aliquoted into single-use microcentrifuge tubes to prevent repeated freeze-thaw cycles, which degrade peptide structural stability. Reconstituted liquid aliquots should be maintained at 2°C to 8°C for short-term active experimentation (up to 30 days) or frozen at -20°C for up to 90 days. Proper environmental controls ensure consistent dosage metrics throughout longitudinal research projects.
For academic institutions, contract research organizations (CROs), and biotechnology firms undertaking large-scale studies, standard retail unit purchasing can create budgetary constraints. Procuring CJC-1295 DAC through institutional bulk channels optimizes grant funding and lowers per-vial expenditure while maintaining lot consistency.
PX1 Research provides customized procurement programs for verified laboratory facilities. Institutional buyers can access bulk tier pricing, reserved lot allocations, and specialized analytical documentation through our dedicated wholesale program, guaranteeing continuity across long-term experimental models.
PX1 Research is dedicated to supplying the scientific community with ultra-pure research peptides manufactured exclusively within the United States. Operating out of state-of-the-art facilities compliant with Current Good Manufacturing Practice (cGMP) standards, PX1 enforces multi-tiered testing protocols for every synthesis lot.
All CJC-1295 DAC vials undergo independent, third-party laboratory verification (RP-HPLC, ESI-MS, LAL Endotoxin) to ensure absolute batch-to-batch consistency. To support active project timelines, orders ship directly from domestic fulfillment centers in California and Arizona, with same-day dispatch available Monday through Friday for fast, reliable delivery.
What factors determine the overall CJC-1295 DAC cost for research labs?
The cost of CJC-1295 DAC is determined by synthesis complexity (specifically attaching the maleimidopropionic acid linker), multi-stage RP-HPLC purification, and independent third-party analytical testing such as ESI-MS and endotoxin screening.
How does the Drug Affinity Complex (DAC) modify the function of CJC-1295?
The DAC modification enables the CJC-1295 peptide to covalently bind to serum albumin via the Cys34 residue in preclinical models, extending its half-life from minutes to several days compared to unmodified GHRH analogs.
What analytical documents are supplied with CJC-1295 DAC from PX1 Research?
Every lot of CJC-1295 DAC is accompanied by a lot-specific Certificate of Analysis (COA) generated by an independent ISO 17025 accredited laboratory, including RP-HPLC chromatograms, mass spectrometry reports, and LAL endotoxin test results.
What is the purity specification for PX1 Research CJC-1295 DAC?
PX1 Research guarantees a minimum purity threshold of >98% as verified by RP-HPLC, with sequence identity confirmed by ESI-MS mass spectrometry.
How does CJC-1295 DAC differ from CJC-1295 Without DAC in laboratory studies?
CJC-1295 DAC binds to albumin for a prolonged, multi-day biological half-life, resulting in continuous growth hormone elevation. CJC-1295 Without DAC lacks the binding linker, yielding a brief half-life suitable for studying short, pulsatile GH spikes.
What solvent is recommended for reconstituting CJC-1295 DAC?
For most cell culture and preclinical applications, sterile bacteriostatic water (0.9% benzyl alcohol) or sterile physiological saline is recommended depending on specific assay protocols.
What are the acceptable endotoxin levels for research-grade CJC-1295 DAC?
PX1 Research enforces a strict endotoxin standard of <0.5 EU/mg, verified via quantitative LAL testing to prevent confounding inflammatory responses in sensitive in vitro and in vivo models.
Does PX1 Research offer volume discounts or bulk accounts for institutional buyers?
Yes, PX1 Research offers tiered pricing and reserved lot allocation for institutional laboratories, universities, and CROs through our wholesale program.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.